{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Swerdlow NR"],"funding":["NIA NIH HHS","RRD VA"],"pagination":["355-362"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12416332"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["91(1)"],"pubmed_abstract":["<h4>Background</h4>The uncompetitive NMDA antagonist, memantine (MEM), enhances prepulse inhibition of startle (PPI) across species. MEM is used to treat Alzheimer's disease (AD); conceivably, its acute impact on PPI might be used to predict a patient's sensitivity to MEM's therapeutic effects.<h4>Objective</h4>To begin to test this possibility, we studied MEM effects on PPI and related measures in AD patients.<h4>Methods</h4>18 carefully screened individuals with AD (mean age = 72.8 y; M:F=9 : 9) completed double-blind order-balanced testing with MEM (placebo versus 20 mg), assessing acoustic startle magnitude, habituation, PPI, and latency.<h4>Results</h4>Fifteen out of 18 participants exhibited reliable startle responses. MEM did not significantly impact startle magnitude or habituation"],"journal":["Journal of Alzheimer's disease : JAD"],"pubmed_title":["Preliminary Evidence that Memantine Enhances Prepulse Effects on Startle Magnitude and Latency in Patients with Alzheimer's Disease."],"pmcid":["PMC12416332"],"funding_grant_id":["IK2 RX003395","IK1 RX003683","R01 AG059640","P30 AG062429"],"pubmed_authors":["Molina JL","Sprock J","Delano-Wood L","Leger GC","Kotz JE","Joshi YB","Talledo J","Iwanaga D","Light GA","Huege S","Swerdlow NR"],"additional_accession":[]},"is_claimable":false,"name":"Preliminary Evidence that Memantine Enhances Prepulse Effects on Startle Magnitude and Latency in Patients with Alzheimer's Disease.","description":"<h4>Background</h4>The uncompetitive NMDA antagonist, memantine (MEM), enhances prepulse inhibition of startle (PPI) across species. MEM is used to treat Alzheimer's disease (AD); conceivably, its acute impact on PPI might be used to predict a patient's sensitivity to MEM's therapeutic effects.<h4>Objective</h4>To begin to test this possibility, we studied MEM effects on PPI and related measures in AD patients.<h4>Methods</h4>18 carefully screened individuals with AD (mean age = 72.8 y; M:F=9 : 9) completed double-blind order-balanced testing with MEM (placebo versus 20 mg), assessing acoustic startle magnitude, habituation, PPI, and latency.<h4>Results</h4>Fifteen out of 18 participants exhibited reliable startle responses. MEM did not significantly impact startle magnitude or habituation","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023","modification":"2026-06-02T00:35:40.701Z","creation":"2026-05-24T03:07:50.647Z"},"accession":"S-EPMC12416332","cross_references":{"pubmed":["36404550"],"doi":["10.3233/JAD-220769","10.3233/jad-220769"]}}